CN101102762A - 含铁组合物 - Google Patents

含铁组合物 Download PDF

Info

Publication number
CN101102762A
CN101102762A CNA2005800470364A CN200580047036A CN101102762A CN 101102762 A CN101102762 A CN 101102762A CN A2005800470364 A CNA2005800470364 A CN A2005800470364A CN 200580047036 A CN200580047036 A CN 200580047036A CN 101102762 A CN101102762 A CN 101102762A
Authority
CN
China
Prior art keywords
iron
compositions
acid
forms
ferrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800470364A
Other languages
English (en)
Chinese (zh)
Inventor
乔纳森·大卫·博茨
米切尔·I·基施纳
大卫·S·赫尔梅林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amag Pharma USA Inc
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of CN101102762A publication Critical patent/CN101102762A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
CNA2005800470364A 2004-12-22 2005-10-27 含铁组合物 Pending CN101102762A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/020,801 2004-12-22
US11/020,801 US20060134227A1 (en) 2004-12-22 2004-12-22 Compositions including iron

Publications (1)

Publication Number Publication Date
CN101102762A true CN101102762A (zh) 2008-01-09

Family

ID=36596132

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800470364A Pending CN101102762A (zh) 2004-12-22 2005-10-27 含铁组合物

Country Status (11)

Country Link
US (5) US20060134227A1 (enExample)
EP (2) EP1827418A4 (enExample)
JP (2) JP2008525442A (enExample)
CN (1) CN101102762A (enExample)
AR (1) AR052837A1 (enExample)
AU (1) AU2005319679A1 (enExample)
BR (1) BRPI0519265A2 (enExample)
CA (1) CA2591996A1 (enExample)
MX (1) MX2007008021A (enExample)
PE (1) PE20061122A1 (enExample)
WO (2) WO2006068697A2 (enExample)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961338A (zh) * 2012-12-07 2013-03-13 青岛黄海制药有限责任公司 一种多糖铁缓释微丸制剂及其制备方法
WO2015032011A1 (zh) * 2013-09-05 2015-03-12 普惠德生技股份有限公司 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途
CN104474004A (zh) * 2014-12-09 2015-04-01 重庆综艺营养科技有限责任公司 改善贫血的赖氨酸螯合铁生血素
CN104887696A (zh) * 2014-03-04 2015-09-09 天津怀仁制药有限公司 右旋糖酐铁和维生素c的复方制剂
WO2018148922A1 (zh) * 2017-02-17 2018-08-23 普惠德生技股份有限公司 含有亚铁氨基酸螯合物的组合物用于制造治疗肝功能异常的医药品的用途
CN108938585A (zh) * 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
CN109069430A (zh) * 2016-03-15 2018-12-21 索洛特林治疗公司 用于增加哺乳动物体内的铁摄入量的组合物和方法
US10183040B2 (en) 2014-12-01 2019-01-22 Profeat Biotechnology Co., Ltd. Method for regulation of lipid metabolism
CN110464011A (zh) * 2018-08-07 2019-11-19 美安康质量检测技术（上海）有限公司 一种补血营养粉及其制备方法
WO2020125462A1 (zh) * 2018-12-20 2020-06-25 普惠德生技股份有限公司 含有亚铁胺基酸螯合物粒子的组合物用于制备治疗或减缓神经受损相关疾病的医药品的用途
US10702494B2 (en) 2013-09-05 2020-07-07 Profeat Biotechnology Co., Ltd. Method for cancer treatment
CN112168843A (zh) * 2019-07-05 2021-01-05 普惠德生技股份有限公司 经烧结的纳米粒子及其抗病毒的用途
CN113226334A (zh) * 2018-10-31 2021-08-06 迈奥诊断公司 用于确保充足铁摄取量的个性化食品
US11224614B2 (en) 2014-09-15 2022-01-18 Solvotrin Therapeutics Limited Compositions and methods for increasing iron intake in a mammal
CN115531369A (zh) * 2021-06-30 2022-12-30 采翼生医股份有限公司 用于缓解肾脏疾病与器官纤维化的方法
WO2023272693A1 (zh) * 2021-07-01 2023-01-05 思瑰瑞保健食品有限公司 一种维生素c加硫酸亚铁缓控释片及其制备方法

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
WO2007035760A1 (en) * 2005-09-20 2007-03-29 Board Of Regents, The University Of Texas System Enhanced solubility of preformed calcium citrate by adding citric acid
ES2380952T3 (es) * 2005-10-11 2012-05-21 Bayer Consumer Care Ag Mezcla de sales de hierro y cobre que enmascaran el sabor metálico.
EP1790356A1 (de) * 2005-11-24 2007-05-30 Vifor (International) Ag Präparat, umfassend Eisen(III)-Komplexverbindungen und redoxaktive Substanz(en)
CA2953964A1 (en) 2006-01-06 2007-07-19 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
ES2395862T3 (es) * 2006-09-28 2013-02-15 Bayer Consumer Care Ag Mezcla de sales de hierro y de cobre para enmascarar el sabor metálico
US8142803B2 (en) 2007-03-22 2012-03-27 Magceutics, Inc. Magnesium compositions and uses thereof for neurological disorders
ES2769583T3 (es) * 2007-03-22 2020-06-26 Neurocentria Inc Composiciones de magnesio y usos de las mismas
US7816404B2 (en) 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US20090047362A1 (en) * 2007-08-13 2009-02-19 Keith Edward Forrester Method for in-vitro stabilization of heavy metals
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US9125844B1 (en) 2007-09-25 2015-09-08 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
US7964189B1 (en) 2007-09-25 2011-06-21 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
ITMI20071979A1 (it) * 2007-10-12 2009-04-13 Massimo Baldacci Formulazioni farmaceutiche contenenti ferro bisglicinato chelato
US20090124572A1 (en) * 2007-11-09 2009-05-14 Deanna Jean Nelson Iron-containing nutritional supplement
US8535659B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
US8535660B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
US9913806B2 (en) * 2008-06-25 2018-03-13 Fe3 Medical, Inc. Patches and methods for the transdermal delivery of a therapeutically effective amount of iron
WO2010036977A2 (en) * 2008-09-25 2010-04-01 New England Medical Center Hospitals, Inc. Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
JP5702307B2 (ja) * 2009-01-30 2015-04-15 エコラボ インコーポレイティド アルミニウムヒドロキシカルボキシレートビルダーの開発
US8202830B2 (en) 2009-01-30 2012-06-19 Ecolab Usa Inc. Development of an aluminum hydroxydicarboxylate builder
US8821945B2 (en) 2009-04-25 2014-09-02 Fe3 Medical, Inc. Method for transdermal iontophoretic delivery of chelated agents
WO2010136839A1 (en) * 2009-05-29 2010-12-02 Carlo Ghisalberti Use of deferoxamine and related compounds in targeted delivery forms to treat an inflammatory bowel disease
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
US8536106B2 (en) 2010-04-14 2013-09-17 Ecolab Usa Inc. Ferric hydroxycarboxylate as a builder
JP5357102B2 (ja) * 2010-04-27 2013-12-04 日本炉機工業株式会社 石化遺骨灰の製造方法
EP2420243A1 (en) 2010-08-18 2012-02-22 Inovativo Biomedicinas Tehnologiju Instituts, SIA Compositions obtainable from bred beetroot juice to promote iron absorption and blood forming
IT1402142B1 (it) * 2010-09-24 2013-08-28 Just Pharma S R L Formulazione integrativa finalizzata al controllo delle alterazioni multifattoriali ricorrenti nell'anemia da carenza di ferro e per colmare eventuali carenze o aumentati fabbisogni nutrizionali in alcune condizioni fisiopatologiche.
EP2497380A1 (en) * 2011-03-10 2012-09-12 DSM IP Assets B.V. Process for iron supplementation of beverages
WO2012163938A1 (de) 2011-05-31 2012-12-06 Vifor (International) Ag Fe(iii)-2,4-dioxo-1-carbonyl-komplexverbindungen zur behandlung und prophylaxe von eisenmangelerscheinungen und eisenmangelanämien
CA2849732C (en) * 2011-09-22 2019-10-01 Jonathan Bortz Buffered upper gi absorption promoter
EA201590062A1 (ru) * 2012-06-21 2016-02-29 Керикс Байофармасьютикалз, Инк. Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью
US20150250839A1 (en) * 2012-09-11 2015-09-10 Dakota Star Capital Llc Nutritional supplement containing iron
CA2913413C (en) * 2013-06-06 2021-11-23 Amip, Llc Iron supplement
ES2683212T3 (es) * 2013-08-28 2018-09-25 Dsm Ip Assets B.V. Complementación de hierro de un concentrado de caldo
PL3048903T3 (pl) * 2013-08-28 2017-09-29 Dsm Ip Assets B.V. Suplementacja żelaza koncentratu bulionu
US9492421B1 (en) 2013-11-14 2016-11-15 Argent Development Group, Llc Nutritional supplements for treatment of iron deficiency anemia
US9629846B1 (en) 2013-11-14 2017-04-25 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
CN104644557B (zh) * 2013-11-22 2017-10-31 上海宣泰医药科技有限公司 卟啉铁固体分散体及其制备方法
JP2014051535A (ja) * 2013-12-19 2014-03-20 Fujifilm Corp 鉄、カルシウム、又はマグネシウムの吸収を促進する方法
EP3179249A4 (en) * 2014-08-05 2017-07-26 Fujifilm Corporation Nucleated erythrocyte sorting method
US9961886B2 (en) 2014-08-13 2018-05-08 Akeso Biomedical, Inc. Antimicrobial compounds and compositions, and uses thereof
JP5757493B1 (ja) * 2014-09-24 2015-07-29 富田製薬株式会社 経口型鉄分補給用固形組成物及びその製造方法
EP3216782B1 (en) * 2014-11-07 2021-06-02 NPA - Núcleo De Pesquisas Aplicadas LTDA. Iron amino acid compounds, method for preparing iron amino acid compounds, compositions containing iron amino acid compounds, and uses thereof
US20170360075A1 (en) * 2014-12-11 2017-12-21 The Penn State Research Foundation Medical food for the treatment of malaria and/or iron deficiency
ES2880321T3 (es) 2015-08-11 2021-11-24 Akeso Biomedical Inc Composiciones de inhibición de biopelícula que potencian el aumento de peso en el ganado
US10653658B2 (en) 2015-08-11 2020-05-19 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
CN105476953B (zh) * 2015-09-01 2018-10-30 张伟 一种用于补铁的液体制剂及其制备方法
US11517555B2 (en) * 2015-09-04 2022-12-06 Rockwell Medical, Inc. Solid soluble ferric pyrophosphate formulations, kits, and methods using the same
JP6919117B2 (ja) * 2015-12-15 2021-08-18 三菱ケミカル株式会社 鉄化合物含有組成物の粒子、鉄化合物の変色抑制方法、並びに鉄化合物及びビタミンｃ含有組成物
EP3199167A1 (de) 2016-01-28 2017-08-02 G.L. Pharma GmbH Arzneimittel zur behandlung von eisenmangelzuständen mit folsäuredefizit
ES2891773T3 (es) * 2016-05-20 2022-01-31 Obshestvo S Ogranichennoj Otvetstvennostju Vikzdorove Zhivotnyh Composición inyectable que comprende un complejo de dextrano de hierro y vitaminas para prevenir y tratar la anemia
CN109069533A (zh) * 2016-05-26 2018-12-21 普惠德生技股份有限公司 含有亚铁氨基酸螯合物的组合物用于制造降低乳酸的药物的用途
CN106265731B (zh) * 2016-09-30 2019-07-19 广西科技大学 硫酸亚铁骨架型缓释滴丸的制备方法
MA50229A (fr) * 2017-09-11 2020-07-22 Pharmacosmos Holding As Composés complexes de fer à usage thérapeutique
CN108635370A (zh) * 2018-07-13 2018-10-12 山东达因海洋生物制药股份有限公司 一种含有右旋糖酐铁的组合物制剂及其制备方法
EP3860621A4 (en) * 2018-10-05 2022-07-06 Ampersand Biopharmaceuticals, Inc. IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY
EP3900719A4 (en) 2018-12-20 2022-08-03 Profeat Biotechnology Co. Ltd. COMPOSITION CONTAINING AN AMINO ACID FERROUS PARTICLE AND ITS USE IN THE PREPARATION OF A PHARMACEUTICAL PRODUCT FOR THE TREATMENT OR IMPROVEMENT OF A PANCREAS-RELATED DISEASE
IL315206A (en) 2021-02-11 2024-10-01 Thermolife Int Llc A method of administering nitric oxide gas
WO2023023029A1 (en) * 2021-08-16 2023-02-23 Thermolife International, Llc Iron supplement compositions and methods of use thereof
CN114028423B (zh) * 2021-12-13 2023-05-23 广东粤港澳大湾区国家纳米科技创新研究院 修饰的纳米氧化铁在制备预防和/或治疗炎性肠病的药物中的应用
CN114288320A (zh) * 2021-12-29 2022-04-08 珠海天翼医药技术开发有限公司 一种猪用口服补铁剂及其制备方法
CN114767710B (zh) * 2022-04-12 2023-07-07 中山大学 甘氨酸亚铁在治疗类风湿关节炎中的应用
CN116636620B (zh) * 2023-05-25 2025-02-14 南昌大学 一种乌鸡蛋清肽组合物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933108A (en) * 1960-02-03 1963-08-08 Haessle Ab Improvements in or relating to pharmaceutical iron preparations
GB1266356A (enExample) * 1968-08-08 1972-03-08
GB1292820A (en) * 1969-08-28 1972-10-11 Aspro Nicholas Ltd Haematinic preparations
GB1338071A (en) * 1970-11-25 1973-11-21 Laso Martinez V Pharmaceutical iron preparations
US3773929A (en) * 1972-11-02 1973-11-20 Diagnostic Data Inc Pharmaceutical compositions comprising orgotein and their use
US4362710A (en) * 1980-07-04 1982-12-07 Nissan Gosei Kogyo Co., Ltd. Feeds for baby pigs, process for preparing the same and method of breeding baby pigs
US4599152A (en) * 1985-05-24 1986-07-08 Albion Laboratories Pure amino acid chelates
US4863898A (en) * 1986-02-06 1989-09-05 Albion International, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
US4752479A (en) * 1986-05-27 1988-06-21 Ciba-Geigy Corporaton Multi vitamin and mineral dietary supplement with controlled release bioavailable iron
US4830716B1 (en) * 1986-07-03 1999-12-07 Albion Int Preparation of pharmaceutical grade amino acid chelates
US5070085A (en) * 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US4822816A (en) * 1987-04-10 1989-04-18 Oxycal Laboratories, Inc. Compositions and methods for administering vitamin C
FR2642420B1 (fr) * 1989-01-27 1991-09-06 Valpan Sa Labo Pharma Nouvelle forme galenique a liberation programmee contenant une association de sels ferreux, d'acide succinique et d'acide ascorbique
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
HU207799B (en) * 1991-07-24 1993-06-28 Beres Export Import Rt Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis
US5662922A (en) * 1992-01-20 1997-09-02 Christensen; Borge Holm Iron-containing composition for the prevention of anaemia and a method for producing the composition
US5516925A (en) * 1994-08-23 1996-05-14 Albion International, Inc. Amino acid chelates having improved palatability
JP2590449B2 (ja) * 1995-04-21 1997-03-12 農林水産省畜産試験場長 新生子牛の造血機能の改善及び貧血の予防方法
PL184140B1 (pl) * 1995-10-27 2002-09-30 Procter & Gamble Napój w proszku
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
CA2230801A1 (en) * 1998-02-27 1999-08-27 Stanley H. Zlotkin Composition comprising micro-encapsulated iron
US6495177B1 (en) * 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement
CN1396908A (zh) * 2000-01-28 2003-02-12 宝洁公司 美味的精氨酸化合物及其用于心血管健康的应用
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
US6716814B2 (en) * 2001-08-16 2004-04-06 Albion International, Inc. Enhancing solubility of iron amino acid chelates and iron proteinates
US6906038B2 (en) * 2001-08-29 2005-06-14 Abbott Laboratories Methods for alleviating mucositis
US20030190355A1 (en) * 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
US7994217B2 (en) * 2002-05-02 2011-08-09 Xanodyne Pharmaceuticals, Inc. Prenatal multivitamin/multimineral supplement
US20060148690A1 (en) * 2002-07-08 2006-07-06 Lydie Bougueleret Secreted peptides
US20030045473A1 (en) * 2002-07-19 2003-03-06 Sarama Robert Joseph Compositions, kits, and methods for cardiovascular health
US8007846B2 (en) * 2006-01-18 2011-08-30 Albion International, Inc. Mixed amino acid/mineral compounds having improved solubility

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109223724A (zh) * 2009-07-21 2019-01-18 凯克斯生物制药公司 柠檬酸铁剂型
CN108938585A (zh) * 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
CN102961338B (zh) * 2012-12-07 2015-03-18 青岛黄海制药有限责任公司 一种多糖铁缓释微丸制剂及其制备方法
CN102961338A (zh) * 2012-12-07 2013-03-13 青岛黄海制药有限责任公司 一种多糖铁缓释微丸制剂及其制备方法
WO2015032011A1 (zh) * 2013-09-05 2015-03-12 普惠德生技股份有限公司 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途
CN104955452A (zh) * 2013-09-05 2015-09-30 普惠德生技股份有限公司 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途
CN104955452B (zh) * 2013-09-05 2017-06-09 普惠德生技股份有限公司 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途
US10702494B2 (en) 2013-09-05 2020-07-07 Profeat Biotechnology Co., Ltd. Method for cancer treatment
CN104887696A (zh) * 2014-03-04 2015-09-09 天津怀仁制药有限公司 右旋糖酐铁和维生素c的复方制剂
CN104887696B (zh) * 2014-03-04 2018-06-29 天津怀仁制药有限公司 右旋糖酐铁和维生素c的复方制剂
US11224614B2 (en) 2014-09-15 2022-01-18 Solvotrin Therapeutics Limited Compositions and methods for increasing iron intake in a mammal
US10183040B2 (en) 2014-12-01 2019-01-22 Profeat Biotechnology Co., Ltd. Method for regulation of lipid metabolism
CN104474004A (zh) * 2014-12-09 2015-04-01 重庆综艺营养科技有限责任公司 改善贫血的赖氨酸螯合铁生血素
CN109069430A (zh) * 2016-03-15 2018-12-21 索洛特林治疗公司 用于增加哺乳动物体内的铁摄入量的组合物和方法
CN109069430B (zh) * 2016-03-15 2022-09-23 索洛特林治疗公司 用于增加哺乳动物体内的铁摄入量的组合物和方法
US11224615B2 (en) 2016-03-15 2022-01-18 Solvotrin Therapeutics Ltd Compositions and methods for increasing iron intake in a mammal
CN110198709A (zh) * 2017-02-17 2019-09-03 普惠德生技股份有限公司 含有亚铁氨基酸螯合物的组合物用于制造治疗肝功能异常的医药品的用途
WO2018148922A1 (zh) * 2017-02-17 2018-08-23 普惠德生技股份有限公司 含有亚铁氨基酸螯合物的组合物用于制造治疗肝功能异常的医药品的用途
CN110464011A (zh) * 2018-08-07 2019-11-19 美安康质量检测技术（上海）有限公司 一种补血营养粉及其制备方法
CN113226334A (zh) * 2018-10-31 2021-08-06 迈奥诊断公司 用于确保充足铁摄取量的个性化食品
WO2020125462A1 (zh) * 2018-12-20 2020-06-25 普惠德生技股份有限公司 含有亚铁胺基酸螯合物粒子的组合物用于制备治疗或减缓神经受损相关疾病的医药品的用途
CN113260358A (zh) * 2018-12-20 2021-08-13 普惠德生技股份有限公司 含有亚铁胺基酸螯合物粒子的组合物用于制备治疗或减缓神经受损相关疾病的医药品的用途
WO2020125464A1 (zh) * 2018-12-20 2020-06-25 普惠德生技股份有限公司 含有亚铁胺基酸螯合物粒子的组合物用于制备治疗或减缓自体免疫相关疾病的医药品的用途
CN112168843A (zh) * 2019-07-05 2021-01-05 普惠德生技股份有限公司 经烧结的纳米粒子及其抗病毒的用途
CN115531369A (zh) * 2021-06-30 2022-12-30 采翼生医股份有限公司 用于缓解肾脏疾病与器官纤维化的方法
CN115531369B (zh) * 2021-06-30 2024-03-08 采翼生医股份有限公司 用于缓解肾脏疾病与器官纤维化的方法
WO2023272693A1 (zh) * 2021-07-01 2023-01-05 思瑰瑞保健食品有限公司 一种维生素c加硫酸亚铁缓控释片及其制备方法

Also Published As

Publication number Publication date
JP2008525445A (ja) 2008-07-17
JP2008525442A (ja) 2008-07-17
BRPI0519265A2 (pt) 2009-01-06
EP1827419A4 (en) 2011-08-17
AU2005319679A1 (en) 2006-06-29
US20090028962A1 (en) 2009-01-29
WO2006068697A3 (en) 2006-12-21
PE20061122A1 (es) 2006-10-16
AR052837A1 (es) 2007-04-04
US20160022631A1 (en) 2016-01-28
WO2006068729A3 (en) 2007-01-18
EP1827418A4 (en) 2011-08-24
WO2006068729A2 (en) 2006-06-29
MX2007008021A (es) 2008-04-11
CA2591996A1 (en) 2006-06-29
EP1827418A2 (en) 2007-09-05
US20110015150A1 (en) 2011-01-20
US20060134227A1 (en) 2006-06-22
WO2006068697A2 (en) 2006-06-29
EP1827419A2 (en) 2007-09-05
US20130189374A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
CN101102762A (zh) 含铁组合物
US20090035385A1 (en) Compositions including iron
US20030190355A1 (en) Modified release minerals
Geisser Safety and efficacy of iron (III)-hydroxide polymaltose complex
KR20110128329A (ko) 인산염 흡착제
WO2010050179A1 (ja) ５－アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とする成人病の予防・改善剤
US6197763B1 (en) Use of metal complexes to treat gastrointestinal infections
CA2421410C (en) Iron compositions
Nagpal et al. Iron formulations in pediatric practice
GB2374008A (en) Compositions including copper and their uses
RU2541092C2 (ru) Бисглицинат-хелат железа для использования в пероральном лечении анемии у пациентов с целиакией
RU2437653C1 (ru) Способ лечения и профилактики желудочно-кишечных болезней новорожденных телят
HK1116672A (en) Compositions including iron
JPH07215868A (ja) 細胞内グルタチオンを刺激する方法及び組成物
DE3936319C3 (de) Phosphatbinder zur oralen Verabreichung
US5665385A (en) Dietary metal supplements
US20030198695A1 (en) Herbo-mineral composition
JPH0240045B2 (enExample)
US20220160619A1 (en) Effervescent Drug Formulations
WO2024263116A1 (en) A stable capsule composition with gastro-resistant pellets for the treatment of iron deficiency anemia
JP2002068981A (ja) 末期ガン患者の食欲不振および味覚異常を改善する医薬
Choudhury Iron Formulations in Pediatric Practice Jitender Nagpal
Neve Pharmaceutical forms containing trace elements for humans
Moiseev Iron preparations intramuscularly. Venofer, solution for intravenous administration. Possible side effects

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1116672

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080109

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1116672

Country of ref document: HK